论文部分内容阅读
Gastric cancer is one of the most frequent human malignancies and the second leading cause of cancer-related death in the world.Human epidermal growth factor receptor 2(HER2)is overexpressed in~20%of gastric cancers.[1] A number of new HER2 targeted compounds such as trastuzumab,pertuzumab,lapatinib,which are currently undergoing phase Ⅱ and Ⅲ clinical testing.[1] Compare to the currently approved standard treatment.